173 related articles for article (PubMed ID: 33737617)
1. Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers.
Kamimura K; Suda T; Fukuhara Y; Okuda S; Watanabe Y; Yokoo T; Osaki A; Waguri N; Ishikawa T; Sato T; Aoyagi Y; Takamura M; Wakai T; Terai S
Sci Rep; 2021 Mar; 11(1):6255. PubMed ID: 33737617
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Growth-Arrest-Specific Transcript 5 Improved Cisplatin Sensitivity in Hepatocellular Carcinoma Through Sponging miR-222.
Zhao P; Cui X; Zhao L; Liu L; Wang D
DNA Cell Biol; 2020 Apr; 39(4):724-732. PubMed ID: 32213078
[TBL] [Abstract][Full Text] [Related]
3. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL
Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740
[TBL] [Abstract][Full Text] [Related]
6. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.
Osaki A; Suda T; Kamimura K; Tsuchiya A; Tamura Y; Takamura M; Igarashi M; Kawai H; Yamagiwa S; Aoyagi Y
Cancer Med; 2013 Feb; 2(1):86-98. PubMed ID: 24133631
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
Meng W; Tai Y; Zhao H; Fu B; Zhang T; Liu W; Li H; Yang Y; Zhang Q; Feng Y; Chen G
Med Sci Monit; 2017 Mar; 23():1295-1304. PubMed ID: 28291769
[TBL] [Abstract][Full Text] [Related]
8. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
Zhou J; Chen Q
FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
10. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells.
Zhang H; Yu QL; Meng L; Huang H; Liu H; Zhang N; Liu N; Yang J; Zhang YZ; Huang Q
Arch Biochem Biophys; 2020 Oct; 693():108571. PubMed ID: 32898567
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
Ueda S; Shirabe K; Morita K; Umeda K; Kayashima H; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
Ann Surg Oncol; 2011 Apr; 18(4):1204-11. PubMed ID: 21076943
[TBL] [Abstract][Full Text] [Related]
12. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.
Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F
Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489
[TBL] [Abstract][Full Text] [Related]
13. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
Shen J; Lin H; Li G; Jin RA; Shi L; Chen M; Chang C; Cai X
Oncotarget; 2016 May; 7(22):32088-99. PubMed ID: 27050071
[TBL] [Abstract][Full Text] [Related]
14. Daurisoline inhibits hepatocellular carcinoma progression by restraining autophagy and promoting cispaltin-induced cell death.
Xue L; Liu P
Biochem Biophys Res Commun; 2021 Jan; 534():1083-1090. PubMed ID: 33213840
[TBL] [Abstract][Full Text] [Related]
15. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
16. Histone Acetyltransferase 1 Promotes Cell Proliferation and Induces Cisplatin Resistance in Hepatocellular Carcinoma.
Jin X; Tian S; Li P
Oncol Res; 2017 Jul; 25(6):939-946. PubMed ID: 27938492
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
Ou Y; Zhai D; Wu N; Li X
Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
[TBL] [Abstract][Full Text] [Related]
19. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression.
Huang X; Li Z; Zhang Q; Wang W; Li B; Wang L; Xu Z; Zeng A; Zhang X; Zhang X; He Z; Li Q; Sun G; Wang S; Li Q; Wang L; Zhang L; Xu H; Xu Z
Mol Cancer; 2019 Mar; 18(1):71. PubMed ID: 30927924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
